Prediabetes Market (By Drug Class: Diguanide, Thiazolidinediones, Glucagon-like Peptide-1 Agonists (GLP-1), SGLT2 Inhibitors, DPP-4 Inhibitors, Others; By Age Group: Children (12-18 years), Adults (18-49), Elderly (50+)) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Prediabetes Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Prediabetes Market, by Drug Class, 2024-2033
8.1.1. Diguanide
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Thiazolidinediones
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Glucagon-like Peptide-1 Agonists (GLP-1)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. SGLT2 Inhibitors
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. DPP-4 Inhibitors
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2033)
9.1. Prediabetes Market, by Age Group, 2024-2033
9.1.1. Children (12-18 years)
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Adults (18-49)
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Elderly (50+)
9.1.3.1. Market Revenue and Forecast (2021-2033)
10.1. North America
10.1.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.1.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.1.3.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.1.4.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.3.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.4.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.5.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.2.6.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.3.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.4.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.5.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.3.6.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.3.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.4.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.5.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.4.6.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.5.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.5.3.2. Market Revenue and Forecast, by Age Group (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Drug Class (2021-2033)
10.5.4.2. Market Revenue and Forecast, by Age Group (2021-2033)
11.1. SciMar
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boston Therapeutics
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Valbiotis
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. RESVERLOGIX
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Caelus Health
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Aphaia Pharma
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AstraZeneca
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bristol-Myers Squibb
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample